Graduate Master Student, Tarbiat Modares University, Iran
Mr. Hadi Alizadeh is a Masterās graduate in Molecular Genetics from Tarbiat Modares University, Tehran, with a thesis on AGPAT3 gene and cisplatin resistance in ovarian cancer cells. His research encompasses gene expression analysis, drug discovery, and epigenomic profiling, focusing on chemoresistance mechanisms in cancer. He has contributed to various publications and presented at international conferences. Skilled in PCR, RNA-seq, flow cytometry, and bioinformatics, he is proficient in machine learning and molecular dynamics. Hadi has been recognized for his academic excellence, ranking highly in national exams. He also has hands-on experience in medical genetics and as a teaching assistant. š§¬šš¬
Publication Profile
Orcid
Education
Mr. Hadi Alizadeh completed his Master’s in Molecular Genetics at Tarbiat Modares University, Tehran, from October 2021 to November 2023, achieving an impressive average of 18.2/20. His thesis, titled “Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian cancer cell line,” was supervised by Dr. Soltani. Prior to this, he earned a Bachelor’s degree in Genetics from Islamic Azad University, North Tehran, from October 2016 to May 2020, with a strong academic performance, securing an average of 17.83/20. His solid educational background highlights his commitment to molecular genetics and cancer research. šš§¬
Research Experience
Mr. Hadi Alizadeh’s research experience includes significant work in molecular genetics and cancer research. For his Master’s thesis, he explored AGPAT3 gene as a regulator of cisplatin resistance in ovarian cancer cells, performing RNA-seq and various functional assays like RT-qPCR, western blotting, and apoptosis assays, revealing AGPAT3’s role in survival and cell cycle arrest under cisplatin treatment. He also studied the synergistic effect of dendrosomal nano-curcumin (DNC) with cisplatin in reducing cisplatin resistance. Additionally, he worked on epigenomic profiling of oxaliplatin-resistant HCT116 colorectal cancer cells and drug discovery targeting mTORC1 signaling. š§¬š»
Honors & Awards šš
Mr. Hadi Alizadeh has demonstrated exceptional academic achievements throughout his career. In 2021, he ranked 18th out of nearly 10,000 participants in the national entrance exam for medical genetics in the healthcare system, showcasing his expertise and dedication. Additionally, he secured the 25th position among approximately 7,000 candidates in the national entrance exam for a Masterās program in genetics. These prestigious rankings highlight his strong academic foundation and passion for genetics research, setting the stage for his future contributions to the field. šš
Professional Experience š¼š¬
Mr. Hadi Alizadeh has gained valuable hands-on experience in various research and clinical settings. As a volunteer at Imam Khomeini Hospital in Tehran, he collected samples and performed RNA extraction for various projects. In his role as an apprentice at the Cytogenetic Lab, he conducted karyotyping as part of clinical genetic analyses, gaining key insights into genetic disorders. Additionally, as a Genetic Laboratory Technician prior to his Masterās, Mr. Alizadeh contributed to the COVID-19 response by performing RNA extraction and real-time PCR on samples, further honing his technical expertise in molecular genetics. š§¬š¬
Research Focus
Mr. Hadi Alizadeh’s research primarily focuses on molecular genetics and cancer biology. His work explores the mechanisms of chemoresistance in cancer, particularly involving the mTORC1 signaling pathway and its role in platinum-based chemotherapy resistance. He also investigates the epigenomic and transcriptomic changes related to chemoresistance in colorectal cancer cells. His expertise extends to drug discovery, with a focus on molecular dynamics and virtual screening for targeting cancer resistance mechanisms. Alizadeh’s research contributes significantly to understanding cancer cell survival and potential therapeutic strategies. š§¬šš”
- Introduction of AGPAT3 gene as a regulator of cisplatin resistance in A2780 ovarian cancer
cell line (under review after revision in PLOS ONE)
- Ā Phosphatidic acid as a cofactor of mTORC1 in platinum-based chemoresistance: Mechanisms
and therapeutic potential (Review article) (Published)
- Ā Epigenomic and Transcriptomic Profiling of Oxaliplatin Resistant HCT116 Colorectal
Cancer Cells Reveals Super-Enhancer-Driven Mechanisms of Chemoresistance
(Bioinformatic article) (Revision in Scientific Reports)
- Comparison of Machine Learning Algorithms and Feature Selection Methods for Identifying
Important Features of Expression Data (Manuscript preparation)
- Bioinformatic Analysis to find drugs Inhibiting mTORC1 as a Phosphatidic AcidDisplacement Strategy (Manuscript preparation)
- Ā Comparison of Signaling Pathways and Genetic Modifications of Cancer Stem Cells with
Normal Stem Cells (Review article) (ready to submit)